

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/007501 A1

(51) International Patent Classification⁷: C07D 487/04,
A61K 31/407, A61P 19/00, 35/00

(21) International Application Number:
PCT/GB2003/002957

(22) International Filing Date: 15 July 2003 (15.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0216525.6 16 July 2002 (16.07.2002) GB
0217239.3 25 July 2002 (25.07.2002) GB
60/418,524 15 October 2002 (15.10.2002) US

(71) Applicant (for all designated States except US): AMURA
THERAPEUTICS LIMITED [GB/GB]; Incenta House,
Horizon Park, Barton Road, Cambridge CB3 7AJ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): QUIBELL, Martin
[GB/GB]; c/o Amura Therapeutics Limited, Incenta House,
Horizon Park, Barton Road, Cambridge CB3 7AJ (GB).
RAY, Peter, Christopher [GB/GB]; Roselea, Blairholyle,
Port of Monteith, By Kippen, FK8 3LF (GB). WATTS,
John Paul [GB/GB]; c/o Amura Therapeutics Limited, In-
centa House, Horizon Park, Barton Road, Cambridge CB3
7AJ (GB).

(74) Agents: SHEARD, Andrew, Gregory et al.; Andrew
Sheard, Patent Attorney, P.O. Box 521, Berkhamsted,
Hertfordshire, HP4 1YP (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to the identity of the inventor (Rule 4.17(i)) for the fol-
lowing designations AE, AG, AL, AM, AT, AU, AZ, BA, BB,
BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK,
DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ,
TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY,
CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

[Continued on next page]

(54) Title: BIOLOGICALLY ACTIVE COMPOUNDS



(57) Abstract: Compounds of general formula (I) wherein: Z = CR³R⁴, where R³ and R⁴ are independently chosen from C₀₋₇-alkyl
P₁ = CR⁵R⁶, P₂ = O, CR⁷R⁸ or NR⁹, Y = CR¹⁰R¹¹-C(O) or CR¹⁰R¹¹-C(S) or CR¹⁰R¹¹-S(O) or CR¹⁰R¹¹-SO₂(X)_n, CR¹⁶R¹⁷ (W)_n = O, S,
C(O), S(O) or S(O)₂- or NR¹⁸ (V)_m = C(O), C(S), S(O), S(O)₂, S(O)₂NH, OC(O), NHC(O), NHS(O), NHS(O)₂, OC(O)NH, C(O)NH
or CR¹⁹R²⁰, C=N-C(O)-OR¹⁹ or C=N-C(O)-NHR¹⁹, U = a stable 5- to 7-membered monocyclic or a stable 8- to 11-membered
bicyclic ring which is either saturated or unsaturated, and which includes zero to four heteroatoms and their salts, hydrates, solvates,
complexes and prodrugs are inhibitors of cathepsin K and other cysteine protease inhibitors and are useful as therapeutic agents,
for example in osteoporosis, Paget's disease gingival diseases such as gingivitis and periodontitis, hypercalcaemia of malignancy,
metabolic bone disease, diseases involving matrix or cartilage degradation, in particular osteoarthritis and rheumatoid arthritis and
neoplastic diseases. The compounds are also useful for validating therapeutic target compounds.



MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW,

ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designation US
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/02957

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D487/04 A61K31/407 A61P19/00 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 02 057270 A (INCENTA LTD ;QUIBELL MARTIN (GB)) 25 July 2002 (2002-07-25) cited in the application claim 1	1-59
A	WO 00 69855 A (TAYLOR STEVEN ;MEDIVIR UK LTD (GB); QUIBELL MARTIN (GB); PEPTIMMUN) 23 November 2000 (2000-11-23) the whole document	1-59
A	WO 98 50533 A (FENWICK ASHLEY EDWARD ;GRIBBLE ANDREW D (GB); SMITHKLINE BEECHAM P) 12 November 1998 (1998-11-12) the whole document	1-59



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

- "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the International search

19 September 2003

Date of mailing of the International search report

29/09/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Baston, E

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 03/02957

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02057270	A	25-07-2002	WO 02057270 A1	25-07-2002
WO 0069855	A	23-11-2000	AU 763694 B2	31-07-2003
			AU 4772200 A	05-12-2000
			BR 0010553 A	02-07-2002
			CA 2374297 A1	23-11-2000
			EP 1178986 A2	13-02-2002
			WO 0069855 A2	23-11-2000
			JP 2002544274 T	24-12-2002
WO 9850533	A	12-11-1998	AU 7562598 A	27-11-1998
			BR 9809306 A	04-07-2000
			CN 1255161 T	31-05-2000
			EP 1003846 A1	31-05-2000
			HU 0002247 A2	28-05-2001
			JP 2001525804 T	11-12-2001
			NO 995434 A	05-11-1999
			NZ 337889 A	28-09-2001
			PL 336856 A1	17-07-2000
			TR 9902766 T2	21-02-2000
			WO 9850533 A1	12-11-1998
			US 2002013360 A1	31-01-2002
			ZA 9803762 A	06-11-1998